It is believed that with the development of targeting technology and drug targeting carriers, anti-CD47 drugs will be targeted and quantitatively acted on local tumor tissues, especially tumors such as malignant meningioma, so as to achieve the effective cure of tumors. The gene discussed is CD47; the disease is neoplasm.